Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · Real-Time Price · USD
1.740
+0.160 (10.13%)
At close: Oct 9, 2025, 4:00 PM EDT
1.760
+0.020 (1.15%)
After-hours: Oct 9, 2025, 7:50 PM EDT
10.13%
Market Cap123.73M
Revenue (ttm)6.65M
Net Income (ttm)-37.52M
Shares Out 71.11M
EPS (ttm)-0.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,095,048
Open1.720
Previous Close1.580
Day's Range1.670 - 1.860
52-Week Range0.243 - 2.010
Beta0.36
AnalystsStrong Buy
Price Target3.13 (+79.89%)
Earnings DateNov 11, 2025

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral pr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2017
Employees 23
Stock Exchange NASDAQ
Ticker Symbol OVID
Full Company Profile

Financial Performance

In 2024, Ovid Therapeutics's revenue was $566,000, an increase of 44.39% compared to the previous year's $392,000. Losses were -$25.98 million, -49.49% less than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $3.13, which is an increase of 79.89% from the latest price.

Price Target
$3.13
(79.89% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ovid Therapeutics Inc. - Special Call

Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO...

6 days ago - Seeking Alpha

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issue...

6 days ago - GlobeNewsWire

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un...

6 days ago - GlobeNewsWire

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for ...

2 months ago - GlobeNewsWire

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un...

2 months ago - GlobeNewsWire

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP cost...

3 months ago - GlobeNewsWire

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, ha...

5 months ago - GlobeNewsWire

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move i...

7 months ago - GlobeNewsWire

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant u...

7 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today...

8 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today...

8 months ago - GlobeNewsWire

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditi...

1 year ago - GlobeNewsWire

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti...

1 year ago - Accesswire

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti...

1 year ago - Accesswire

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut...

1 year ago - Accesswire

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut...

1 year ago - Accesswire

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut...

1 year ago - Accesswire

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ...

1 year ago - Accesswire

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut...

1 year ago - Accesswire

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditio...

1 year ago - GlobeNewsWire

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut...

1 year ago - Accesswire

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti...

1 year ago - Accesswire

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti...

1 year ago - Accesswire

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ...

1 year ago - Accesswire

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti...

1 year ago - Accesswire